Karyopharm Sets Accelerated-Approval Filing Plan for Selinexor in Myelofibrosis

Company Karyopharm Therapeutics Event Type Regulatory Pathway Plan (Planned Accelerated-Approval Filing) Modality Oral exportin-1 (XPO1) inhibitor plus JAK1/2 inhibitor combination Asset Selinexor plus ruxolitinib Target XPO1 (exportin-1) and JAK1/2 Disease Area JAK-inhibitor-naive myelofibrosis Summary Karyopharm plans to submit an August 2026 supplemental New Drug Application…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Weekly Market Insight

Lilly – Ajax JAK2 Deal ($2.3B)
argenx Acquires Forte for $2.2 Billion
Ultrasound Genetic Medicine Platform Advances Toward Clinic
AstraZeneca Licenses Dizal’s Zegfrovy for Up to $1.5B